Page 1 | Search Results | Blood | American Society of Hematology

1-15 of 15

Sort by

Sort Order Select

Journal Articles

Impairment of AML Engraftment to the Bone Marrow Niche Following Inhibition of TGF-Beta Signaling

Ashley Hamilton, PhD, Katie Foster, PhD, Dominique Bonnet, PhD

Blood (2014) 124 (21): 4372.

https://doi.org/10.1182/blood.V124.21.4372.4372

Published: 2014

Journal Articles

Misregulation Of The PRC2 Complex In CML Stem Cells Confers Sensitivity To An EZH2 Inhibitor

Mary T Scott, PhD, Koorosh Korfi, PhD, Paolo Gallipoli, PhD, Peter Saffrey, PhD, Heather Jorgensen, PhD, Michelle Cruz, Ashley Hamilton, PhD, Amy Sinclair, Andrew Crossan, PhD, Emmanuel Normant, PhD, Vidya Balasubramanian, Tessa L. Holyoake, PhD, David Vetrie, PhD

Blood (2013) 122 (21): 2710.

https://doi.org/10.1182/blood.V122.21.2710.2710

Published: 2013

Journal Articles

Inhibition of Autophagy in Combination with Ponatinib or Dual PI3K/mTOR Inhibition to Improve Treatment Response for Both Bcr-Abl Dependent and Independent Mechanisms of TKI-Resistance in CML

G.Vignir Helgason, PhD, Elaine K Allan, Samanta Mariani, Arunima Mukhopadhyay, Maria Karvela, Sara Galavotti, Alessandra Audia, Ashley Hamilton, Franck E. Nicolini, MD, PhD, Brian J. Druker, Paolo Salomoni, Bruno Calabretta, Tessa L. Holyoake, PhD, FRCP, FRCPath

Blood (2012) 120 (21): 1664.

https://doi.org/10.1182/blood.V120.21.1664.1664

Published: 2012

Journal Articles

Chronic myeloid leukemia stem cells are not dependent on Bcr-Abl kinase activity for their survival

Ashley Hamilton, G. Vignir Helgason, Mirle Schemionek, Bin Zhang, Svetlana Myssina, Elaine K. Allan, Franck E. Nicolini, Carsten Müller-Tidow, Ravi Bhatia, Valerie G. Brunton, Steffen Koschmieder, Tessa L. Holyoake

Blood (2012) 119 (6): 1501–1510.

https://doi.org/10.1182/blood-2010-12-326843

Published: 2012

Includes: Supplemental data

Journal Articles

BCR-ABL enhances differentiation of long-term repopulating hematopoietic stem cells

Mirle Schemionek, Christian Elling, Ulrich Steidl, Nicole Bäumer, Ashley Hamilton, Tilmann Spieker, Joachim R. Göthert, Martin Stehling, Amy Wagers, Claudia S. Huettner, Daniel G. Tenen, Lara Tickenbrock, Wolfgang E. Berdel, Hubert Serve, Tessa L. Holyoake, Carsten Müller-Tidow, Steffen Koschmieder

Blood (2010) 115 (16): 3185–3195.

https://doi.org/10.1182/blood-2009-04-215376

Published: 2010

Journal Articles

Mtss1 Suppresses BCR-ABL Induced Cell Migration and Is Downregulated in CML Stem Cells.

Mirle Schemionek, Shuchi Agrawal, PhD, Martin Stehling, PhD, Daniel G. Tenen, MD, Ashley Hamilton, Tessa Holyoake, MD, PhD, Ulrich Steidl, MD, PhD, Wolfgang E. Berdel, MD, Albrecht Schwab, MD, Carsten Müller-Tidow, MD, Steffen Koschmieder, MD

Blood (2008) 112 (11): 1077.

https://doi.org/10.1182/blood.V112.11.1077.1077

Published: 2008

Journal Articles

Growth Factor Deprivation Combined with Prolonged Inhibition of BCR-ABL Does Not Eradicate Functional CML Stem Cells

Ashley Hamilton, Gudmundur V Helgason, Elaine Allan, Michael J. Alcorn, PhD, Franck E Nicolini, MD, PhD, Allison Blair, PhD, BSc, Mirle Schemionek, Steffen Koschmieder, MD, Valerie G Brunton, Tessa L Holyoake

Blood (2008) 112 (11): 4222.

https://doi.org/10.1182/blood.V112.11.4222.4222

Published: 2008

Journal Articles

Targeting Autophagy Potentiates Imatinib-Induced Cell Death in Philadelphia Positive Cells Including Primary CML Stem Cells.

Blood (2008) 112 (11): 1070.

https://doi.org/10.1182/blood.V112.11.1070.1070

Published: 2008

Journal Articles

BMS-214662 potently induces apoptosis of chronic myeloid leukemia stem and progenitor cells and synergizes with tyrosine kinase inhibitors

Mhairi Copland, Francesca Pellicano, Linda Richmond, Elaine K. Allan, Ashley Hamilton, Francis Y. Lee, Roberto Weinmann, Tessa L. Holyoake

Blood (2008) 111 (5): 2843–2853.

https://doi.org/10.1182/blood-2007-09-112573

Published: 2008

Includes: Supplemental data

Journal Articles

Response: Conventional Western blotting techniques will not reliably quantify p210 BCR-ABL

Mhairi Copland, Ashley Hamilton, Tessa L. Holyoake

Blood (2007) 109 (3): 1336.

https://doi.org/10.1182/blood-2006-11-054031

Published: 2007

Journal Articles

BMS-214662 Eliminates CML Stem Cells and Is Active Against Blast Crisis CML and Cells Expressing BCR-ABL Kinase Mutations.

Mhairi Copland, MD, Linda Richmond, BSc, Ashley Hamilton, BSc, Elaine K. Allan, BSc, Junia V. Melo, MD, PhD, Tessa L. Holyoake, MD, PhD

Blood (2006) 108 (11): 739.

https://doi.org/10.1182/blood.V108.11.739.739

Published: 2006

Journal Articles

Dasatinib (BMS-354825) targets an earlier progenitor population than imatinib in primary CML but does not eliminate the quiescent fraction

Mhairi Copland, Ashley Hamilton, Lucy J. Elrick, Janet W. Baird, Elaine K. Allan, Niove Jordanides, Martin Barow, Joanne C. Mountford, Tessa L. Holyoake

Blood (2006) 107 (11): 4532–4539.

https://doi.org/10.1182/blood-2005-07-2947

Published: 2006

Journal Articles

BMS-214662 Targets Quiescent Chronic Myeloid Leukaemia Stem Cells and Enhances the Activity of Both Imatinib and Dasatinib (BMS-354825).

Mhairi Copland, MD, Ashley Hamilton, BSc, Elaine K. Allan, BSc, Valerie Brunton, PhD, Tessa L. Holyoake, MD, PhD

Blood (2005) 106 (11): 693.

https://doi.org/10.1182/blood.V106.11.693.693

Published: 2005

Journal Articles

Dasatinib (BMS-354825) Has Increased Activity Against Bcr-Abl Compared to Imatinib in Primary CML Cells In Vitro , but Does Not Eradicate Quiescent CML Stem Cells.

Mhairi Copland, MD, Ashley Hamilton, BSc, Janet W. Baird, PhD, Martin Barow, PhD, Elaine K. Allan, BSc, Lucy J. Elrick, PhD, Tessa L. Holyoake, MD, PhD

Blood (2005) 106 (11): 695.

https://doi.org/10.1182/blood.V106.11.695.695

Published: 2005

Journal Articles

Imatinib Mesylate Does Not Inhibit BCR-ABL Kinase Activity in CML Stem Cells In Vitro .

Lucy J. Elrick, PhD, Ashley Hamilton, BSc, Michael W. Deininger, MD PhD, Tessa L. Holyoake, MD PhD

Blood (2004) 104 (11): 1979.

https://doi.org/10.1182/blood.V104.11.1979.1979

Published: 2004

NARROW

Impairment of AML Engraftment to the Bone Marrow Niche Following Inhibition of TGF-Beta Signaling

Misregulation Of The PRC2 Complex In CML Stem Cells Confers Sensitivity To An EZH2 Inhibitor

Inhibition of Autophagy in Combination with Ponatinib or Dual PI3K/mTOR Inhibition to Improve Treatment Response for Both Bcr-Abl Dependent and Independent Mechanisms of TKI-Resistance in CML

Chronic myeloid leukemia stem cells are not dependent on Bcr-Abl kinase activity for their survival

BCR-ABL enhances differentiation of long-term repopulating hematopoietic stem cells

Mtss1 Suppresses BCR-ABL Induced Cell Migration and Is Downregulated in CML Stem Cells.

Growth Factor Deprivation Combined with Prolonged Inhibition of BCR-ABL Does Not Eradicate Functional CML Stem Cells

Targeting Autophagy Potentiates Imatinib-Induced Cell Death in Philadelphia Positive Cells Including Primary CML Stem Cells.

BMS-214662 potently induces apoptosis of chronic myeloid leukemia stem and progenitor cells and synergizes with tyrosine kinase inhibitors

Response: Conventional Western blotting techniques will not reliably quantify p210 BCR-ABL

BMS-214662 Eliminates CML Stem Cells and Is Active Against Blast Crisis CML and Cells Expressing BCR-ABL Kinase Mutations.

Dasatinib (BMS-354825) targets an earlier progenitor population than imatinib in primary CML but does not eliminate the quiescent fraction

BMS-214662 Targets Quiescent Chronic Myeloid Leukaemia Stem Cells and Enhances the Activity of Both Imatinib and Dasatinib (BMS-354825).

Dasatinib (BMS-354825) Has Increased Activity Against Bcr-Abl Compared to Imatinib in Primary CML Cells In Vitro , but Does Not Eradicate Quiescent CML Stem Cells.

Imatinib Mesylate Does Not Inhibit BCR-ABL Kinase Activity in CML Stem Cells In Vitro .

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only